Phase composition control of calcium phosphate nanoparticles for tunable drug delivery kinetics and treatment of osteomyelitis. II. Antibacterial and osteoblastic response

Vuk Uskoković, Tejal A. Desai
Therapeutic Micro and Nanotechnology Laboratory, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California 94158-2330

Received 6 August 2012; accepted 20 August 2012
Published online 31 October 2012 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/jbm.a.34437

Abstract: Osteomyelitis has been traditionally treated by the combination of long-term antibiotic therapies and surgical removal of diseased tissue. The multifunctional material was developed in this study with the aim to improve this therapeutic approach by: (a) enabling locally delivered and sustained release of antibiotics at a tunable rate, so as to eliminate the need for repetitive administration of systemically distributed antibiotics; and (b) controllably dissolving itself, so as to promote natural remineralization of the portion of bone lost to disease. We report hereby on the effect of previously synthesized calcium phosphates (CAPs) with tunable solubilities and drug release timescales on bacterial and osteoblastic cell cultures. All CAP powders exhibited satisfying antibacterial performance against Staphylococcus aureus, the main causative agent of osteomyelitis. Still, owing to its highest drug adsorption efficiency, the most bacteriostatically effective phase was amorphous CAP with the minimal inhibitory concentration of less than 1 mg/mL. At the same time, the positive cell response and osteogenic effect of the antibiotic-loaded CAP particles was confirmed in vitro for all the sparsely soluble CAP phases. Adsorption of the antibiotic onto CAP particles reversed the deleterious effect that the pure antibiotic exerted on the osteogenic activity of the osteoblastic cells. The simultaneous osteogenic and antimicrobial performance of the material developed in this study, altogether with its ability to exhibit sustained drug release, may favor its consideration as a material base for alternative therapeutic approaches to prolonged antibiotic administration and surgical debridement typically prescribed in the treatment of osteomyelitis. © 2012 Wiley Periodicals, Inc.

Key Words: calcium phosphate, drug delivery, osteomyelitis, osteoblasts, osteogenesis

INTRODUCTION

The prevalence of bone disease is expected to increase as the population ages.1 The number of hip and knee replacement procedures performed in the US has, for example, doubled in the past decade, while the number of reported cases of bone infection accompanying those has been also steadily increasing in proportion with the number of surgeries performed.2 The majority of bone diseases are, however, systemic in nature, for example osteoporosis, calling for similar systemic approaches to their treatment. Other diseases, some of which are infectious, for example osteomyelitis, exhibit a pronounced local character and demand equally localized treatments to prevent their spreading and systemic deterioration of the skeletal support of the organism as a whole. Local surgical operations that involve permanent removal of the diseased tissue, long-term antibiotic therapies, and occasional implantation of hard tissue substitutes are typically prescribed to treat bone infection.3 To improve on this partly invasive approach that often leaves the postoperative patients even frailer than before the treatment, novel therapies for infectious hard tissue diseases are actively being sought.4–8

This study aims at improving this rather imperfect contemporary medical approach to treating osteomyelitis by developing materials able to: (a) deliver a localized and sustained flux of antibiotics so as to eliminate the need for their repetitive administration and systemic distribution in the body; and (b) promote natural remineralization of the portion of bone lost to disease through their osteogenic nature. Calcium phosphates present a natural choice for the drug delivery carrier in the treatment of osteomyelitis because they share the chemical composition with the
TABLE I. CAP Phases Synthesized as a Part of this Study

<table>
<thead>
<tr>
<th>Phase</th>
<th>Chemical Formula</th>
<th>Space Group</th>
<th>pKsp at 37°C</th>
<th>Ca/P Molar Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCPP</td>
<td>Ca(H2PO4)2·H2O</td>
<td>Triclinic pT</td>
<td>1.14</td>
<td>0.5</td>
</tr>
<tr>
<td>DCPA</td>
<td>CaHPO4</td>
<td>Triclinic pT</td>
<td>7.0</td>
<td>1</td>
</tr>
<tr>
<td>β-CPP</td>
<td>Ca3P2O7</td>
<td>Tetragonal P4</td>
<td>18.5</td>
<td>1</td>
</tr>
<tr>
<td>ACP</td>
<td>Ca3(PO4)2·nH2O</td>
<td></td>
<td>25</td>
<td>1.3–5</td>
</tr>
<tr>
<td>HAP</td>
<td>Ca10(PO4)6(OH)2</td>
<td>Pseudohexagonal P63/m</td>
<td>117.3</td>
<td>1.67</td>
</tr>
</tbody>
</table>

ACP, amorphous calcium phosphate (data pertain to the phase obtainable at pH 9–1); CPP, calcium pyrophosphate; DCPA, dicalcium phosphate anhydrous; HAP, hydroxyapatite; MCPP, monocalcium phosphate monohydrate.

inorganic component of bone. In the first part of this study, we described the synthesis of five different calcium phosphate (CAP) phases that covered the full range of solubility products for CAPs, from the most soluble monocalcium phosphate (MCPP; pKsp 1.14) to the least soluble hydroxyapatite (HAP; pKsp 117.3) (Table I). The release of physically absorbed proteins or small organics used as model drugs was shown to be directly conditioned by the dissolution rate of the powder, allowing for simple, stoichiometry-controlled tunability of the drug release kinetics, ranging from 1–2 h to 1–2 years. In this part, we report on the results of our looking at the effect of these different monophasic CAP nanopowders on bacterial and MC3T3-E1 osteoblastic cell cultures.

EXPERIMENTAL

Preparation of CL-loaded CAPs

Loading of CAP powders with clindamycin phosphate (CL, Tokyo Chemical Industry) followed the identical approach as that reported in the first part of the study for BSA and fluorescein, the two model drugs used to investigate the release profiles of the carriers. Loading with CL was qualitatively confirmed using differential scanning calorimetry (DSC; Calorimetry Sciences Corporation).

Bacterial studies

A single colony of *Staphylococcus aureus* (ATCC 25923) cultured on a blood agar plate over 48 h was stabbed with a pipette tip, which was then placed in 5 mL of 37 mg/mL brain heart infusion (BHI) broth and kept on an incubator shaker (Innova 44) overnight at 37°C and 225 rpm. The turbid broth was collected the following day and 8 mL of it was added to serially diluted samples containing different concentrations of CL in 1 mL of 37 mg/mL BHI broth, for the purpose of determining the minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of the pure drug under the given analytical conditions. The given bacterial concentration (1:125,000 of 5 mL 37 mg/mL BHI broth inoculated overnight with a single bacterial colony) was found to be equal to the standard concentration of 10^5 bacteria per mL after comparing the optical density at λ = 600 nm of a range of serially diluted bacterial broths with 0.5 M McFarland solution (equivalent to ~10^9 bacteria per mL) prepared by mixing 1% BaCl₂ solution and 1% H₂SO₄ in the volume ratio of 1:200, respectively. The dilution yielding the same absorbance as that of 0.5 M McFarland solution was diluted 10^5 times to yield the standard bacterial concentration of 10^5 bacteria per mL. The series of samples was incubated overnight on the incubator shaker and analyzed the following day for their optical density at λ = 600 nm using a Micropack DS-2000 UV/Vis/NIR spectrophotometer. The MIC was determined as the point of intersection of the resulting transmittance versus (CL) curve, and the transmittance of the bacterial broth at zero time point. To assess the antibacterial performance of the CAP particles, different amounts of CL-containing CAP powders, ranging from 1–50 mg were added to 1 mL of 37 mg/mL BHI broth containing 10^5 bacteria, incubated overnight on the incubator shaker and analyzed the following day for their optical density at λ = 600 nm.

Cell culture studies

Mouse calvarial preosteoblastic cell line, MC3T3-E1 subclone 4, was purchased from American Tissue Culture Collection (ATCC, Rockville, MD) and cultured in Alpha Minimum Essential Medium (α-MEM; Gibco) supplemented with 10% fetal bovine serum (FBS, Invitrogen) and without ascorbic acid (AA). The medium was replaced every 48 h and the cultures were incubated at 37°C in a humidified atmosphere containing 5% CO₂. Every 7 days, the cells were detached from the surface of the 75 cm² cell culture flask (Greiner Bio-One) using 0.25 wt % trypsin, washed, centrifuged (1000 rpm × 3 min), resuspended in 10 mL media, and subcultured in 1:7 volume ratio. Cell passages 2–5 were used for the experiments reported hereby. In all experiments, the cells were seeded either in 96-well plates and 100 μL of media at a density of 10^4 cells per well or on glass cover slips placed in 24-well plates and 400 μL of media at a density of 6 × 10^3 cells per well. The cultures were regularly examined under an optical microscope to monitor growth and possible contamination. Near confluence, cells were treated with 2 mg/cm² of CAP/CL particles and 50 μg/mL AA as the mineralization inducer, and incubated for 7–10 days. Alpha-MEM supplemented with 50 μg/mL AA was replenished every 48 h. Cells incubated with pure CL were cultured in the same medium containing 100 μg/mL CL.

After incubation period of 7 days, cells grown in 24-well plates were stained by adding 200 μL of 2 μM calcein AM and 4 μM ethidium homodimer-1 (EthD-1) in phosphate buffer saline (PBS) and incubated at 37°C for 45 min (Invitrogen L-3224). Inverted cover slips containing cells and CAP/CL particles were then mounted on microscope slides wetted with 20 μL of the staining solution and sealed using...
nail polish. Immediately thereafter, the live/dead cell count was performed under an Olympus BX60 optical microscope. Three hours after staining, single plane images of the samples were collected on a confocal laser scanning microscope–C1si (UCSF Nikon Imaging Center) at 60× and 100× magnifications in oil. All the experiments were carried out in quadruplicates. Another staining procedure involved first fixing the cells for 15 min in 3.7% paraformaldehyde. The cells were then washed with PBS 3 × 5 min and then with the blocking solution (PBT = 1% Bovine Serum Albumin (BSA), 0.1% Triton X-100 in PBS) 2 × 5 min. The cells were then blocked and permeabilized in PBT for 1 h, and then incubated in 20 μg/mL 4',6-diaminidine-2-phenylindole dihydrochloride nuclear counterstain (DAPI, Invitrogen), 2 μM calcein AM as HAP/CL-staining compound, and 10 μg/mL phalloidin-tetramethylrhodamine (AlexaFluor 555, Invitrogen), all in PBT for 1 h and then washed with PBS 3 × 5 min. The cover slips containing the fixed and stained cells were mounted onto glass slides using hard set vectashield and nail polish and were subsequently imaged on a confocal laser scanning microscope–C1si (UCSF Nikon Imaging Center) at 100× magnification in oil.

Differentiation of MC3T3-E1 fibroblasts into osteoblast-like cells entails the formation of a mineralized extracellular collagen matrix and the expression of genes associated with the osteoblastic phenotype. After the incubation period of 10 days, cell lysis, reverse transcription (Bio-Rad), and qPCR (Applied Biosystems, StepOnePlus) were performed using the Fast SYBR Green Cells-to-CT kit (Ambion) in accordance with the manufacturer’s instructions. Each experiment was done in quadruplicates, whereas each experimental replica was analyzed for mRNA expression in triplicates (n = 4 × 3). The expressions of one housekeeping gene, β-actin (ACTB), and five osteogenic markers, mouse type I procollagen (Col I), alkaline phosphatase (ALP), osteocalcin (BGLAP), osteopontin (BSP-1), and Runx2 were analyzed. The primer pair sequences used are given in the Supporting Information. The real-time PCR results were analyzed using the ΔΔCt method and all the data were normalized to ACTB expression levels.

RESULTS AND DISCUSSION

Because osteomyelitis can be potentially caused by a variety of infective agents, CL, a wide-range antibiotic commonly prescribed to treat infections caused by an array of gram-positive and gram-negative bacteria, aerobic and anaerobic, as well as fungi and protozoa, was chosen as a model antibiotic for this study. The most serious side effect of its usage is reduced diversity of the intestinal microbiota and acute pseudomembranous colitis. The phosphate form of CL, its protractive form owing to higher permeability of the cell membrane, was used due to its higher adsorption capacity to CAP, as a result of Ca^{2+}-PO_{4}^{3-} interaction, as well as higher solubility in aqueous media. Antibiotics can be broadly classified to two categories: concentration-effective and time-effective, with CL belonging to the second category. Whereas the effective application of concentration-dependent antibiotics depends on the ability to bring their concentration in the target area to 10–12 times the MIC in a short period of time, for CL as a time-dependent antimicrobial, a direct correlation exists between the duration of the antimicrobial concentration exceeding the MIC and the time that it takes to eradicate the pathogen, with the bactericidal effect being optimal at 4–5 times the MIC in vitro. Finding ways to sustain the period during which the concentration of CL exceeds the MIC for the given bacterial population is thus of vital importance in making the therapies involving this antibiotic more effective. Assessment of the antibacterial performance of CL-loaded CAP powders of different phase composition has correspondingly presented a central subject of this study. To complement this evaluation of the effectiveness of CAP/CL powders in eradicating the pathological source of infection, studies were also carried out to assess their osteogenic effects on osteoblastic cells in vitro.

Pharmacokinetic performance of particles prepared in this work can be divided to the following kinetic factors: (1) release from the dosage form; (2) distribution to the site of action; and (3) reaction with the targeted biochemical species. Since (2) is a very fast step as the particles are meant to be surgically implanted in the vicinity of inflammation, the slowest rate between (1) and (3) will kinetically determine the drug performance. These two factors were in this work first evaluated separately by (a) measuring the rate of release of the drug from the particles, and (b) determining the MIC of the pure drug. Only then were these two combined and looked at in couple. As the contents of the bacteriostatic agents as low as 0.2% were shown to be effective in treating dental infection, CL loading efficiency, presumably comparable to that of fluorescein, should not be a critical factor in ensuring the antimicrobial performance of CAP/CL particles.

The limited burst release in the first 24 h exhibited by all CAP powders presents a vital precondition for their effective acting in a bacteriostatic or bactericidal manner. Initial deviations from zero-order kinetics, often considered undesirable when sustained drug delivery is performed to treat nonbacterial pathologies, are thus vital for suppressing bacterial infection by controlled delivery of antibiotics, as timely transcendence of the MIC is required to prevent the rise of resistance to the given antibiotic among the bacterial population. Previous studies on the MIC of CL with respect to S. aureus have shown that, depending on the bacterial strain, the MIC can lie anywhere between 1 and 500 μg/mL. As shown in Figure 1(a), extrapolation of the linear range of the curve that represents the optical density of BHI broths inoculated with the standard concentration of a single colony of S. aureus (10^5 bacteria per mL) at λ = 600 nm as a function of concentration of the drug indicates that any (CL) > 24 μg/mL suppresses the bacterial growth. At (CL) > 150 μg/mL, the plateau is reached on the given curve, suggesting that the latter is the minimal bactericidal concentration (MBC) for the actual conditions. As the latter was found to be more than four times higher than the MIC, CL can be, in this case, considered as a bacteriostat rather than a bactericide.
The optical transparence at $\lambda = 600$ nm and visual appearance of BHI broths inoculated with *S. aureus* and incubated overnight with different amounts of CL-containing CAP powders as a function of the concentration of the latter are shown in Figure 1(b) and Supporting Information Figure S2, respectively. The graph demonstrates different MIC levels for different CAP powders all of which lie below that of 15 mg/mL for MCPM (Table II). The addition of MCPM dropped the pH to below 6 and it has been previously shown that pH drop from 7.4 to 5.5 increases the MIC of CL with respect to *S. aureus* 16-fold. A similar effect was observed in this study: although CL itself is stable at low pH and the CL content in MCPM/CL powder was determined using UV absorption to > 5 wt %, the effective (CL) equaled only 0.2%. This effect is explained by the exceptional tolerance of *S. aureus* to low pH and the decreased activity of CL, alongside many other antibiotics, in acidic media. The most effective antibacterial performance was exhibited by ACP powders, in which case less than 1 mg/mL was sufficient to prevent the bacterial growth. This is presumably due to their highest level of burst dissolution among all the CAP powders, directly relatable to the comparatively high rate of initial drug release. Coupled with the earlier observed small molecule drug release timescale of 1–2 months, closest to the duration of antibiotic therapy for bone infection, these results favor ACP for the medical application conceived hereby more than any other CAP phase. 

Controlled drug delivery by means of implantable nanoparticles has been shown to produce local concentrations of the released drug well beyond the MIC levels and is considered a more effective means of delivery compared to intravenous route for specific applications that include lowly vascular tissues, including those comprising bone. Although CL resistance does occur in *S. aureus* as well as

**TABLE II. MIC Values and Drug Percentage for Different CAP Powders Loaded with CL**

<table>
<thead>
<tr>
<th>CAP Phase</th>
<th>MIC (mg/mL)</th>
<th>Estimated Effective Content of CL in CAP/CL (wt %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAP</td>
<td>2.5</td>
<td>3</td>
</tr>
<tr>
<td>ACP</td>
<td>&lt;1</td>
<td>5</td>
</tr>
<tr>
<td>DCPA</td>
<td>12</td>
<td>0.8</td>
</tr>
<tr>
<td>MCPM</td>
<td>15</td>
<td>0.2</td>
</tr>
</tbody>
</table>

*FIGURE 1.* Optical transparence at $\lambda = 600$ nm of BHI broths inoculated with *S. aureus* ($10^5$ bacteria per mL) and different amounts of CL (a) and different CAP phases loaded with CL (b), following 24 h incubation.
among patients with osteomyelitis and with prior antibiotics exposure, the antibacterial assessment reported hereby suggests that the application of antibiotic-loaded CAP particles analyzed would not be any more likely than the traditional therapy to result in spontaneous drug resistance during treatment.

Cell culture studies
On incubation with osteoblastic cells for up to 21 days, none of the CAP powders loaded with CL except MCPM/CL exhibited toxic effects on the cells. The percentage of dead cells was < 2% for all CAP/CL powders except MCPM/CL, with no significant difference from the negative control. Cells incubated with MCPM were, however, fully rounded and dead at the time of their visualization [Fig. 4(a)]. Moreover, it was noticed earlier that acidification entails dissolution of MCPM/CL also increases the MIC of CL required to stop the bacterial growth. This relatively powerful acidic nature of the most soluble CAP powder, MCPM, may present a major obstacle to its in vivo application. However, if the medium was refreshed immediately on the dissolution of the MCPM particles, 1–2 h after their addition, the viability of the cell population was preserved [Fig. 4(b)], despite being significantly decreased (40–60%). This observation provides hope that the flow of body fluids to and from the area of surgical implantation may still prevent the detrimental effects of the very fast dissolution of MCPM, the most acidic CAP phase, in vivo.

The results of fluorescent staining of CAP/CL particles and osteoblastic cells shown in Figures 5 and 6 demonstrate excellent cell adherence and spreading on CAP/CL particles of all sparsely soluble phases remnant in the system after 7 days of incubation: HAP, ACP, and DCPA. The in-plane images in Figure 6 correspondingly display blue-stained cell nuclei elongated in the direction of the particle surface, with red-stained f-actin cytoskeleton fully enwrapping the surface of the CAP/CL microparticles. This observation highlights the advantage of therapeutic implantation of nanoparticulate microscopic blocks, rather than dispersed nanoparticles, in terms of (a) enabling the formation of an osteoconductive surface for the thriving of bone-building cells thereon, and (b) exhibiting satisfying drug loading and release profiles, thus contributing to adequate antibacterial performance of the material.

The results of the gene expression analysis of the effects of various CAP/CL powders on osteoblastic MC3T3-E1 cells are displayed in Figure 7. Transcription levels of BGLAP, a gene encoding for a protein directly involved in mineralization of the extracellular matrix and a key marker for bone formation, were elevated with respect to the housekeeping gene, ACTB, for all CAP/CL powders except MCPM/CL, signifying the mineralization activity of the cells. The expression of all the analyzed osteogenic markers, with the exception of ALP, was upregulated with respect to the negative control, suggesting the positive effect of CAP/CL particles on bone formation in vitro. Interestingly, DCPA, the most soluble phase that does not induce acidification of the medium below the physiological levels, leads to most drastic upregulation of osteogenic markers compared with the control group: BSP-1, BGLAP, Col I, and Runx2. Comparatively high, though still sparse solubility of DCPA led to release of significant amount of phosphate ions, exceeding the critical level of ~3 mM according to solubility data and augmenting the fibroblast-to-osteoblast differentiation effect induced by sole AA. In addition, highly bioresorbable DCPA has been shown earlier to promote a more efficient bone healing process on in vivo implantation compared with HAP. This effect may be accounted for by the fact that aside from providing a surface for cells to spread and thrive on, the osteogenic effect of CAP powders comes also from their release of ions constitutive to newly made bone, the rate of which is higher for DCPA than for ACP and HAP. The only gene whose expression was not consistently upregulated for CAP powders with respect to the control group was ALP, which is normal in view of its multiple roles in both differentiated and undifferentiated cells, as well as pathological

**FIGURE 2.** Averaged color of pure CL, pure ACP and different CAP powders loaded with CL after their annealing to 200°C in air, at the heating rate of 10°C/min. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

**FIGURE 3.** DSC diagrams of pure CL (dashed line) and CL encapsulated within DCPA powder (straight line).
causes of its elevation,

This explains why the only markers found in MCPM cells, fully dead at the time of mRNA collection in the case when the cell growth medium was not replenished after the particles have dissolved, were ALP, Col I, both of which are common to fibroblasts too, and BSP-1. The expression of most analyzed genes in MCPM-incubated cells was markedly lower compared with all other samples, consistent with the lethal effects of the acidification of the medium following its dissolution. The only MCPM gene expression level comparable with the control was BSP-1, not surprising as it is known that its upregulation in cells can be a sign of their unviable response to the drug and that it is a negative regulator of proliferation and differentiation in MC3T3-E1 cells coinciding with its role as a mineralization inhibitor rather than promoter, as BGLAP or Col I. The absolute expression levels were lowest for ALP and BSP-1: less than one-fold difference with respect to the housekeeping gene, a sign of cell viability in view of their augmentation in pathological states. Because Runx2 is a key transcription factor for osteoblast differentiation, the considerable time span of 10 days between mRNA collection and induction of differentiation can explain its comparatively low presence in the cytoplasm.

FIGURE 4. Single plane confocal optical micrographs of fluorescently stained osteoblastic MC3T3-E1 cells following 7 days of incubation with MCPM/CL, in cases when the cell growth medium was replenished 48 h after the addition of the particles (a) and immediately upon their dissolution and drug release (1–2 h) (b). The sizes of the images are 450 × 450 µm (a) or 270 × 270 µm (b).

FIGURE 5. Single plane confocal optical micrographs of fluorescently stained CAP/CL particles (green) and osteoblastic MC3T3-E1 cells (red) following 7 days of incubation in differentiation medium: (a) control; (b) HAP/CL; (c, d) ACP/CL; (e, f) DCPA/CL. The sizes of the images are 450 × 450 µm (a, b, d, e) or 270 × 270 µm (c, f).
FIGURE 6. Single plane confocal optical micrographs of fluorescently stained DCPA/CL, ACP/CL and HAP/CL particles (green) and osteoblastic MC3T3-E1 cells (cytoskeletal f-actin - red; nucleus - blue) following 7 days of incubation in differentiation medium. The sizes of the images are 270 x 270 μm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

FIGURE 7. The effect of CAP particles loaded with CL on the mRNA expression of five different osteogenic markers: BSP-1, ALP, BGLAP, Col I, and Runx2 in osteoblastic MC3T3-E1 cells. mRNA expression was detected by quantitative RT-polymerase chain reaction relative to the housekeeping gene ACTB. Data normalized to expression of ACTB are shown as averages with error bars representing standard deviation. Genes significantly (p < 0.05) upregulated with respect to the control group are marked with *. Genes significantly (p < 0.05) downregulated with respect to the control group are marked with +. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
extent: 1 mg/mL CL solution in the buffered culture media
effect that CL exerts on the cell activity lies in the fact that
antibiotic and the lowest MICs have led to lower levels of
on why the two CAP phases with the highest content of the
S aureus
exerted a satisfactory antibacterial effect against
its dissolution also acidifies the medium to a considerable
promotion of bone growth markers compared with DCPA
induce a decrease in cell viability, whereas effectively eradici-
inducing gene
Col I,
BGLAP , Col I, and Runx2 in osteoblastic MC3T3-E1 cells. mRNA expression was detected by quantitative RT-polymerase chain reaction relative to house-
their incorporation within an osteogenic drug carrier,
were previously reported. These results also shed light
why the two CAP phases with the highest content of the
antibiotic and the lowest MICs have led to lower levels of
promotion of bone growth markers compared with DCPA
with its weaker antibiotic efficacy. A reason for this adverse
effect that CL exerts on the cell activity lies in the fact that
its dissolution also acidifies the medium to a considerable
extent: 1 mg/mL CL solution in the buffered culture media
thus yields pH < 7 at room temperature. In these experi-
ments, [CL] = 100 μg/mL was chosen because of its prox-
imity to the previously determined MIC and MBC for growth
suppression and eradication of S aureus, 25 and 150 μg/mL,
respectively. It also lies in the same range as clinically meas-
ured levels of gentamicin following its local application,53 as
well as in the low range of those of CL released from drug-
impregnated polymeric beads.54 Still, the amount of CL
present in CAP powders proved to be sufficiently low not to
induce a decrease in cell viability, whereas effectively eradici-
the pathogenic source of infection. These results dem-
strate that the osteogenic effect of CAP, the drug carrier,
can not only mitigate but also fully reverse the unviable
effect that the pure drug has on the cells by ensuring its
rather slow release to the environment. The synergy
between CAP and CL is thus able to eliminate the negative
effects that a sole antibiotic component may exert on its
biological milieu, while retaining its antimicrobial potency.

CONCLUSIONS
The multifunctional material developed in this study
exerted a satisfactory antibacterial effect against S aureus,
the main causative agent of osteomyelitis. The most effec-
tive phase in this respect was amorphous CAP, owing to its
highest drug adsorption efficiency and amorphous surface
prone to lattice reorganization via dissolution/recrystalliza-
tion phenomena, entailing facile release of the surface-
bound drug molecules. Coupled with its small molecule
drug release timescale of 1–2 months, closest to the dura-
tion of the conventional antibiotic therapy for bone infec-
tion, amorphous CAP could be potentially favored for the
medical application conceived hereby more than any other
CAP phase. The microscopic CAP particles loaded with the
antibiotic also engaged in an intimate interface with the
osteoblastic cells, suggesting their osteoconductive charac-
ter. All the sparsely soluble antibiotic-loaded CAP powders
had a positive morphological effect on cell spreading, while
not interfering with the cell viability. They additionally
increased osteogenic activity of the osteoblastic cells, as
evidenced by their ability to induce upregulation of genes
encoding for osteocalcin, type I procollagen, and the trans-
scription factor Runx2. The most positive effect of monetite,
that is DCPA, on the expression of osteogenic markers
among all CAP powders suggests a direct correlation
between (a) the release of constitutive ions from an active
surface, particularly phosphates, potent mineralization
inducers in MC3T3-E1 cells, and (b) efficacy in compensat-
ing for the osteogenic inhibition exerted by the pure antibi-
otic. The reduced activity of osteoblast-like cells was found
to be caused by the antibiotic component of the material,
and yet fully reversed when the drug was released from the
sparsely soluble CAP carriers. The simultaneous osteo-
genic and antimicrobial performance of the material devel-
opled in this study, altogether with its ability to exhibit sus-
tained drug release profiles, may favor its consideration as
a material base for alternative therapeutic approaches for
prolonged antibiotic administration and surgical debride-
ment typically prescribed in the treatment of osteomyelitis.

ACKNOWLEDGMENTS
Presented were the results of a study supported by the NIH
grant K99-DE021416. The authors thank Charles Hoover of
UCSF for providing S aureus; Francis Szoka of UCSF for allow-
ing the use of DSC; Feroz Papa lab at UCSF for allowing the use
of qPCR thermocycler; Nikon Imaging Center at UCSF at which
confocal microscopy data were acquired for this study.
REFERENCES


47. Duewelhenke N, Krut O, Eysel P. Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob Agent Chemother 2006;51:54–63.
53. Isefuku S, Joyner CJ, Simpson AHRW. Gentamicin may have an adverse effect on osteogenesis. J Orthop Trauma 2003;17; 212–216.